Immunome (NASDAQ:IMNM) Stock Price Up 4.4% Following Insider Buying Activity

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) was up 4.4% during trading on Thursday after an insider bought additional shares in the company. The company traded as high as $7.68 and last traded at $7.40. Approximately 229,972 shares changed hands during trading, a decline of 73% from the average daily volume of 836,334 shares. The stock had previously closed at $7.09.

Specifically, CEO Clay B. Siegall purchased 137,100 shares of the firm's stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average price of $7.29 per share, with a total value of $999,459.00. Following the completion of the acquisition, the chief executive officer now owns 806,736 shares in the company, valued at $5,881,105.44. This trade represents a 20.47 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CTO Philip Tsai acquired 12,300 shares of the company's stock in a transaction that occurred on Monday, March 24th. The shares were acquired at an average cost of $8.42 per share, with a total value of $103,566.00. Following the purchase, the chief technology officer now directly owns 33,300 shares of the company's stock, valued at $280,386. This trade represents a 58.57 % increase in their position. The disclosure for this purchase can be found here. In other Immunome news, Director Jean Jacques Bienaime bought 7,000 shares of the firm's stock in a transaction on Monday, March 24th. The shares were acquired at an average cost of $8.21 per share, for a total transaction of $57,470.00. Following the purchase, the director now directly owns 23,615 shares of the company's stock, valued at $193,879.15. The trade was a 42.13 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Remove Ads

Analysts Set New Price Targets

IMNM has been the subject of several recent analyst reports. Wedbush reissued an "outperform" rating and set a $33.00 price objective on shares of Immunome in a report on Thursday, March 20th. Stephens reissued an "overweight" rating and issued a $30.00 price target on shares of Immunome in a research note on Thursday, March 20th. Guggenheim lowered their price objective on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, March 20th. Finally, Lifesci Capital started coverage on shares of Immunome in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 target price for the company. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $25.50.

Immunome Stock Performance

The stock's 50 day moving average price is $9.50 and its 200-day moving average price is $11.28. The company has a market cap of $570.83 million, a PE ratio of -0.81 and a beta of 1.93.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The business had revenue of $2.74 million for the quarter, compared to analysts' expectations of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. On average, analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current year.

Hedge Funds Weigh In On Immunome

Large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets bought a new position in shares of Immunome in the fourth quarter worth approximately $70,000. KLP Kapitalforvaltning AS purchased a new stake in Immunome during the 4th quarter valued at $75,000. AlphaQuest LLC grew its holdings in Immunome by 786,700.0% in the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock worth $84,000 after acquiring an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after acquiring an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC purchased a new position in shares of Immunome in the fourth quarter valued at about $95,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.